StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Reaktion

Trifluoroacetic acid → N-(6-(6-chloro-5-(3-(difluoromethoxy)phenylsulfonamido)pyridin-3-yl)-3-(1,2,3,6-tetrahydropyridin-4-yl)imidazo[1,2-b]pyridazin-2-yl)acetamide

HRID 1162496
Drucken

Reaktionsgleichung

Reaktionsgleichung von HRID 1162496
[C:1]([NH:4][C:5]1[N:6]=[C:7]2[CH:12]=[CH:11][C:10]([C:13]3[CH:14]=[N:15][C:16]([Cl:33])=[C:17]([NH:19][S:20]([C:23]4[CH:28]=[CH:27][CH:26]=[C:25]([O:29][CH:30]([F:32])[F:31])[CH:24]=4)(=[O:22])=[O:21])[CH:18]=3)=[N:9][N:8]2[C:34]=1[C:35]1[CH2:40][CH2:39][N:38](C(OC(C)(C)C)=O)[CH2:37][CH:36]=1)(=[O:3])[CH3:2].FC(F)(F)C(O)=O>>[Cl:33][C:16]1[N:15]=[CH:14][C:13]([C:10]2[CH:11]=[CH:12][C:7]3[N:8]([C:34]([C:35]4[CH2:40][CH2:39][NH:38][CH2:37][CH:36]=4)=[C:5]([NH:4][C:1](=[O:3])[CH3:2])[N:6]=3)[N:9]=2)=[CH:18][C:17]=1[NH:19][S:20]([C:23]1[CH:28]=[CH:27][CH:26]=[C:25]([O:29][CH:30]([F:31])[F:32])[CH:24]=1)(=[O:21])=[O:22]
KomponentenVersuchsvorschriftAufarbeitungQuellen und NachweiseNotizen zur Reaktion

Komponenten

3

Edukt 2

HCID 6422Trifluoroacetic acidHCID 57749439tert-butyl 4-(2-acetamido-6-(6-chloro-5-(3-(difluoromethoxy)phenylsulfonamido)pyridin-3-yl)imidazo[1,2-b]pyridazin-3-yl)-5,6-dihydropyridine-1(2H)-carboxylate

Produkt 1

HCID 86631967N-(6-(6-chloro-5-(3-(difluoromethoxy)phenylsulfonamido)pyridin-3-yl)-3-(1,2,3,6-tetrahydropyridin-4-yl)imidazo[1,2-b]pyridazin-2-yl)acetamide

Versuchsvorschrift

A sealable vial was charged with tert-butyl 4-(2-acetamido-6-(6-chloro-5-(3-(difluoromethoxy)phenylsulfonamido)pyridin-3-yl)imidazo[1,2-b]pyridazin-3-yl)-5,6-dihydropyridine-1(2H)-carboxylate (104.0 mg, 151 μmol) and neat trifluoroacetic acid (1.16 mL, 15.1 mmol). The solution was stirred at rt for 1 h. The solution was then concentrated to give N-(6-(6-chloro-5-(3-(difluoromethoxy)phenylsulfonamido)pyridin-3-yl)-3-(1,2,3,6-tetrahydropyridin-4-yl)imidazo[1,2-b]pyridazin-2-yl)acetamide, which was of sufficient purity for further use. Methanol (2.0 mL) was added to the crude residue followed by an aqueous solution of sodium hydroxide (6 N, 502 μl, 3014 μmol). The solution was heated at 50° for 18 h. The solution was concentrated, then taken up in minimal MeOH/DMSO and purified by preparative HPLC (Gilson GX-218, Middletown, Wis.: 5-90% (0.1% TFA in CH3CN) in H2O over 15 min, Phenomenex, Zorbax 00F-4435-UO 150×30 mm, 5 micron) to afford the title compound, N-(5-(2-amino-3-(1,2,3,6-tetrahydropyridin-4-yl)imidazo[1,2-b]pyridazin-6-yl)-2-chloropyridin-3-yl)-3-(difluoromethoxy)benzenesulfonamide (8.6 mg, 8.6% yield) as a yellow solid. LCMS (ESI positive ionization) m/z: 548.1 (M+1); 1H NMR (400 MHz, MeOH) δ ppm 3.12-3.23 (m, 2H); 3.59 (t, J=5.97 Hz, 2H); 3.97-4.08 (m, 2H); 6.35-6.48 (m, 1H); 6.84 (t, J=73.02 Hz, 1H); 7.40-7.46 (m, 1H); 7.49-7.66 (m, 3H); 7.87-7.94 (m, 1H); 7.97-8.04 (m, 1H); 8.79 (dd, J=15.55, 2.25 Hz, 2H).

Aufarbeitung

  1. concentrationThe solution was then concentrated

Quellen und Nachweise

ORD-Eintrag
ord-3fbbe7b7439146f3ac90bed63304d97b
Quelldatensatz
uspto-grants-2010_10
DOI
10.6084/m9.figshare.5104873.v1
Patentnummer
US07820665B2

Notizen zur Reaktion

Auf dieser SeiteKomponentenVersuchsvorschriftAufarbeitungQuellen und NachweiseNotizen zur Reaktion